RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease

Dimitry Ofengeim1,2, Sonia Mazzitelli1,3, Yasushi Ito4, Judy Park DeWitt5, Lauren Mifflin6, Chengyu Zou6, Sudeshna Das7,8, Xian Adiconis7, Hongbo Chen7, Hong Zhu7, Michelle A. Kelliher7, Joshua Z. Levin8, and Junying Yuan9,10

1Department of Cell Biology, Harvard Medical School, Boston, MA 02115; 2Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Cambridge, MA 02139; 3Department of Neurology, Harvard Medical School, Boston, MA 02115; 4Broad Institute, Cambridge, MA 02142; and 5Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605

Contributed by Junying Yuan, August 15, 2017 (sent for review August 11, 2017; reviewed by J. Marie Hardwick and David Rubinsztein)

Dysfunction of microglia is known to play an important role in Alzheimer’s disease (AD). Here, we investigated the role of RIPK1 in microglia mediating the pathogenesis of AD. RIPK1 is highly expressed by microglial cells in human AD brains. Using the amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK1, using both pharmacological and genetic means, reduced amyloid burden, the levels of inflammatory cytokines, and memory deficits. Furthermore, inhibition of RIPK1 promoted microglial degradation of Aβ in vitro. We characterized the transcriptional profiles of adult microglia from APP/PS1 mice and identified a role for RIPK1 in regulating the microglial expression of CH25H and Cst7, a marker for disease-associated microglia (DAM), which encodes an endosomal/lysosomal cathepsin inhibitor named Cystatin F. We present evidence that RIPK1-mediated induction of Cst7 leads to an impairment in the lysosomal pathway. These data suggest that RIPK1 may mediate a critical checkpoint in the transition to the DAM state. Together, our study highlights a non-cell death mechanism by which the activation of RIPK1 mediates the induction of a DAM phenotype, including an inflammatory response and a reduction in phagocytic activity, and connects RIPK1-mediated transcription in microglia to the etiology of AD. Our results support that RIPK1 is an important therapeutic target for the treatment of AD.

Significance

Dysfunction of microglia plays a fundamental role in the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia. However, there is a lack of knowledge about targets that can be safely manipulated for modulating microglia for the treatment of AD. The presence of a unique subtype of disease-associated microglia (DAM) has recently been implicated in mediating pathogenesis of AD. However, the mechanism that promotes the development of DAM is unclear, nor is it known how DAM may modulate the progression of AD. This study demonstrates that RIPK1-dependent transcription promotes DAM and lysosomal defects to mediate the accumulation of amyloid plaques in AD. Thus, targeting RIPK1 may provide an important therapeutic strategy for the treatment of AD.


Reviewers: J.M.H., Johns Hopkins University; and D.R., University of Cambridge.

Conflict of interest statement: Denali Therapeutics has licensed the Necrostatin program (including Nec-1s) from Harvard Medical School. J.Y. is a consultant of Denali Therapeutics.

1D.O. and S.M. contributed equally to this work.

2To whom correspondence should be addressed. Email: juan@hms.harvard.edu.

This article contains supporting information online at www.pnas.org/cgi/doi/10.1073/pnas.1714175114/-/DCSupplemental.
(PS1) transgenic mouse model. We found that, compared with control APP/PS1 animals, plaque burden, and insoluble Aβ levels were strongly reduced in RIPK1−/− mice. Moreover, in both RIPK1−/−, APP/PS1 mice and APP/PS1;Nec-1s, there was a significant reduction in amyloid plaque-associated microglia and the levels of proinflammatory cytokines. These data demonstrate that the kinase activity of RIPK1 mediates the transcriptional up-regulation of Cst7, which encodes an endosomal/lysosomal cathepsin inhibitor named Cystatin F (25), and CH25H in microglia. We present evidence that RIPK1-dependent induction of Cst7 leads to inhibition of cathepsin activity and impairment in the lysosomal pathway. Consistently, inhibition of RIPK1 could promote the degradation of Aβ by microglia in vitro. Together, our study provides a mechanism by which activation of the RIPK1-mediated transcriptional response promotes a DAM state, which in turn impairs the microglial phagocytic capacity. Thus, we propose that RIPK1 is a critical mediator in microglial response to the extracellular environment to promote pathogenesis of AD. Our data provide a strong rationale for blocking RIPK1 as a novel therapeutic for AD.

Results

Levels of RIPK1 Are Increased in AD. To examine whether RIPK1 is involved in the pathophysiology of AD, we performed immunostaining on postmortem cortical tissue from control and AD patients. We identified an increase in overall reactivity of RIPK1 in AD patient-derived brain tissues compared with the control tissues (Fig. 1A, Fig. S1.A–D, and Table S1). To this end, we identified an upper band in the Western blots of RIPK1 in the insoluble fraction of AD samples, which suggests that RIPK1 might be phosphorylated in AD samples (Fig. 1B). To explore the phosphorylation status of RIPK1 in AD, we used a phospho-S166 RIPK1 antibody, a marker for its autophosphorylation and activation (19, 22, 26), and found increased S166 phosphorylation of RIPK1 in AD brain samples, suggesting that RIPK1 is activated in human AD (Fig. 1C). On the other hand, although we observed an increase in levels of TNFα, as previously reported (27, 28), no changes in the mRNA levels of RIPK1 were found in AD (Fig. 1D), suggesting that the increase in the levels of insoluble RIPK1 protein is a result of post-translational control. A significant proportion of RIPK1+ cells in the brains of human AD exhibited microglial morphology and colocalized with the microglial marker IBA1 (Fig. 1E). Taken together, these results suggest that RIPK1 is activated in AD brains and might be involved in regulating disease-associated microglial function.

Inhibition of RIPK1 Kinase Reduces Inflammation in the CNS of the AD Mouse Model. We next used APP/PS1 mice as a model to characterize the functional role of RIPK1 in the development of AD pathology. We first examined the expression of RIPK1 in APP/PS1 mice. Interestingly, similar to the data from human AD cortical samples, RIPK1 levels in the insoluble fraction were significantly elevated in the APP/PS1 mice (6 mo old) (Fig. 1F). This increase of RIPK1 also occurred in IBA1+ microglia around amyloid plaques, as assessed by immunohistochemistry (Fig. 1G). On the other hand, RIPK1 reactivity only showed limited colocalization with GFAP+ astrocytes and did not colocalize with neurons or neuronal processes throughout most of the brain, except there was some overlap of RIPK1 immunostaining with dystrophic neurites (Fig. S1.E–F).

To determine whether RIPK1-dependent signaling mediates the development of disease pathology, we delivered either vehicle or Nec-1s to APP/PS1 mice (5 mo old) for a period of 1 mo. We examined the impact of inhibiting RIPK1 on the numbers of cortical and hippocampal plaques. Nec-1s–treated animals had reduced numbers of Thioflavin S-positive (ThS+) inclusions and Aβ-immunoreactive plaques, compared with vehicle-treated animals (Fig. 2 A and B and Fig. S2). Furthermore, we characterized the levels of soluble and insoluble Aβ species in vehicle-treated and Nec-1s–treated mice and found that the treatment of Nec-1s reduced the levels of both Aβ species (Fig. 2C). Our data suggest that administration of Nec-1s mediates a histological and biochemical reduction of amyloid burden in the APP/PS1 mice.

To assess if pharmacological inhibition of RIPK1 can also rescue behavioral deficits in the APP/PS1 mice, we examined WT and APP/PS1 mice at 5 mo of age in an open field test for the total distance traveled in a new environment. Consistent with the effect of expressing APP/PS1 in promoting hyperactivity of mice (29, 30), APP/PS1 mice showed significant increased spontaneous locomotor activity, illustrated by a significantly greater distance traveled in the testing chamber during the first hour of the open field test compared with WT mice (Fig. 2 D and E). After confirming these data, APP/PS1 mice were then divided into groups so their baseline activity levels did not differ between genotype-matched groups that received vehicle or Nec-1s. APP/PS1 mice and WT controls were tested again after dosing with vehicle or Nec-1s for 30 d (n = 14 mice per genotype and treatment) in the open field test. These results suggest that inhibition of RIPK1 reduced the hyperactivity of APP/PS1 mice to WT levels.

We next used the water T-maze, which requires mice to use visual and spatial cues to locate a submerged escape platform for assessing spatial learning and memory (acquisition trials) and cognitive flexibility (reversal trials). A significant decrease was observed in both the acquisition phase and the reversal phase in 5- to 6-mo-old APP/PS1 mice, as previously reported at this age (31). Importantly, age-matched APP/PS1 mice that were dosed with Nec-1s for 1 mo performed as well as WT mice in both reversal phases (Fig. 2F), suggesting that inhibition of RIPK1 can improve the spatial memory in the APP/PS1 mice.

Inhibition of RIPK1 Kinase Activity Reduces Amyloid Burdens in APP/PS1 Mice. To determine if the kinase activity of RIPK1 is important to drive the pathology in the APP/PS1 mice, we crossed APP/PS1 mice with the kinase-dead RIPK1D138N mice and aged these mice for 6 to 7 mo. To investigate whether genetic inactivation of RIPK1 kinase activity could alter Aβ pathology, we compared the amyloid burden of APP/PS1 and APP/PS1;RIPK1D138N double mutant mice in both cortex and hippocampus. We found that APP/PS1;RIPK1D138N mice had reduced numbers of ThS+ inclusions and Aβ1-42-immunoreactive plaques compared with APP/PS1; WT mice (Fig. 3 A and B). We also measured the CNS levels of soluble and insoluble Aβ1-42. APP/PS1;RIPK1D138N mice had lower levels of both soluble and insoluble levels of Aβ1-42 compared with APP/PS1;WT mice (Fig. 3C). These data show that both pharmacological and genetic inhibition of RIPK1 activity can reduce the amyloid burden of APP/PS1 mice.

To test whether genetic inactivation of RIPK1 can also inhibit APP/PS1-driven behavioral deficits, we assessed WT, RIPK1D138N, APP/PS1; WT, and APP/PS1;RIPK1D138N mice in the open field test. Similar to our data using Nec-1s, genetic inactivation of RIPK1 kinase activity reduced the hyperactivity of APP/PS1 mice (Fig. 3 D and E). Furthermore, inactivation of RIPK1 in APP/PS1;RIPK1D138N mice also improved the performance relative to APP/PS1;WT mice in the water T-maze (Fig. 3F). Thus, loss of RIPK1 kinase activity can reduce the memory deficits in APP/PS1 mice.

RIPK1 Is a Key Mediator of Disease-Associated Microglial Response. Our data suggest that inhibiting RIPK1, by either pharmacological or genetic means, reduces amyloid burden and improves memory function in APP/PS1 mice. We next took both an in vivo and in vitro approach to investigate the mechanism through which RIPK1 may mediate pathology in AD. Using primary mouse cortical neurons in culture, we did not observe an effect of Nec-1s in directly protecting oligomeric Aβ1-42–induced neuronal...
death (Fig. S34). On the other hand, zVAD.fmk, a pancaspase inhibitor, inhibited neuronal cell death induced by Aβ1–42, confirming the role of caspases in mediating Aβ-induced neuronal cell death (32, 33). Consistently, the enriched expression of RIPK1 was found predominantly in microglia (Fig. 1). We hypothesized that microglia might be a key effector of the deleterious signaling mediated by RIPK1 in AD. Interestingly, we found that the number of plaque-associated microglia was reduced in APP/PS1;RIPK1Δ138N mice compared with APP/PS1;WT mice (Fig. 4A and B). Furthermore, the levels of the proinflammatory cytokines TNFα and IL6 were reduced in APP/PS1;RIPK1Δ138N mice compared with APP/PS1;WT mice (Fig. 4C). These data suggest that inhibiting RIPK1 blocks some of the deleterious disease-associated microglial response in the APP/PS1 mice.

To investigate the role of RIPK1 in the microglial response to Aβ, we treated primary WT and RIPK1Δ138N mouse-derived microglia with oligomeric Aβ1–42 in the presence or absence of Nec-1s. We found that either the presence of the RIPK1 inhibitor or genetic ablation of the kinase activity of RIPK1 reduced the production of TNFα and IL6 from microglia, in vitro, in response to Aβ1–42 (Fig. 4D and Fig. S3B). Furthermore, we found an increase in the levels of p-S166 RIPK1 in cultured microglia stimulated by Aβ1–42 peptides, suggesting that Aβ1–42 can promote the activation of RIPK1 (Fig. 4E). Both pharmacological
and genetic inhibition of RIPK1 kinase activity enhanced the ability of microglia to degrade synthetic oligomeric Aβ_{1-42}. We found that inhibition of RIPK1 by Nec-1s reduced both supernatant and intracellular levels of Aβ_{1-42} in microglia (Fig. 4 F–H). This result was confirmed using FITC-labeled Aβ_{1-42} (Fig. S3 C and D). These data suggest that RIPK1 activation may alter the dynamics of Aβ turnover. Thus, inhibition of RIPK1 increases the turnover of Aβ_{1-42} and the production of proinflammatory cytokines by microglia.

**RIPK1 Mediates an Altered Microglial Response.** While our data using primary microglial culture suggests a role for RIPK1 signaling in these cells, we wanted to directly investigate RIPK1 signaling in acutely isolated brain microglia. We isolated microglia from adult (5- to 6-mo-old) WT, RIPK1^{D138N}, APP/PS1;WT, and APP/PS1;RIPK1^{D138N} mice (Dataset S1). Consistent with an efficient isolation of adult microglial cells using CD11b and CD45 as surface markers for microglia, the top transcripts identified by RNA sequencing in these cells were either exclusive to microglial cells or highly enriched in these cells (Fig. S4 and Table S2). As reported (34), we did not detect a significant increase in the population of CD45^{high} and CD11b^{+} cells in the CNS of 5- to 6-mo-old APP/PS1 mice compared with that of WT mice. These data suggest that, at this age, the majority of CD11b^{+} cells are resident microglia. This is in contrast to older APP/PS1 animals (35) that have an increase in CD45^{high} and CD11b^{+} cells compared with WT mice.

**Fig. 2.** Pharmacological inhibition of RIPK1 attenuates biochemical pathology and behavioral deficits in the APP/PS1 mouse. Five-month-old WT and APP/PS1 mice were given vehicle or Nec-1s for 1 mo. The brain slices from these mice were examined by histology for ThS+ inclusions in the cortex (A and B) and hippocampus (B). (C) Nec-1s inhibited the APP/PS1-induced increase of ThS+ plaques. Furthermore, Nec-1s attenuated the increase of both soluble and insoluble (guanidine-soluble) Aβ_{42,40} in APP/PS1 mice (n = 6 to 8 mice per group). ns, not significant. (D) WT and APP/PS1 mice (≤5-mo old) were given vehicle or Nec-1s for 1 mo and examined in the open field test (n = 7 to 9 male mice per group) for 60 min; the total ambulatory distance the mice traveled was quantified. (E) The distance the mice traveled during 5-min bins was also assessed in the APP/PS1 mice. (F) WT and APP/PS1 mice (≤6-mo old) were assessed using the water T-maze to evaluate spatial working memory. A significant decrease was observed in both the acquisition phase (Left) and the reversal phase (Middle) in 6-mo-old APP/PS1 mice compared with WT mice (n = 12 to 14 male mice per group). (Right) The same mice were randomly split into two groups per genotype and given either vehicle or Nec-1s for 1 mo and then reassessed in the reversal phase of the water T-maze. *P < 0.05; **P < 0.01; one-way ANOVA followed by Bonferroni’s post hoc test.
We performed RNA sequencing of CD45+/CD11b+ cells to examine the role of the RIPK1-dependent transcriptional program activated in APP/PS1 mice. The pathway that was prominently altered specifically in microglia from APP/PS1 mice was the ubiquitin/proteasome system (Fig. 5A). This is consistent with the idea that the protein turnover machinery is altered in aging and neurodegeneration (36). Our study suggests that this alteration of protein homeostasis may at least in part occur in microglia. Many key components of both the ubiquitin/proteasomal (UPS) and lysosomal degradation systems are highly expressed in microglial cells. One intriguing possibility is that alterations in the proteasomal/lysosomal systems can promote the activation of RIPK1. To directly test this possibility, we subjected primary isolated microglial cells or a microglial cell line to either inhibitors of the UPS or the lysosomal activity. Interestingly, we found that the inhibition of either UPS or the lysosomal system led to rapid induction of RIPK1 activation as assessed by p-S166 RIPK1 which could be inhibited by Nec-1s (Fig. 5B and C). This activation of RIPK1 was at least in part similar to that observed following Toll-like receptor activation induced by LPS (Fig. 5B). These data suggest that RIPK1 may regulate some aspects of proteostasis in microglial cells.

Our data thus far suggest that RIPK1 mediates an altered microglial state in APP/PS1 mice. Interestingly, RNA-seq expression analysis identified a module with ~149 genes that were up-regulated in APP/PS1 microglia compared with that of WT, RIPK1D138N, and APP/PS1:RIPK1D138N microglia (Fig. 5D). We validated a subset of our RNA-seq hits by real-time quantitative reverse-transcription-PCR (qRT-PCR) (Fig. S4B). These data suggest that there may be a transcriptional program that is activated in microglia from APP/PS1 mice in a RIPK1-dependent manner. We performed pathway analysis (MSigDB; Molecular Signatures Database) (37)
Fig. 5. Defects in protein turnover promote the activation of RIPK1 in APP/PS1 microglia. (A) Pathways and processes that are enriched in APP/PS1-derived microglia transcriptome compared with WT mice. Analysis was done using gene set enrichment analysis (MSigDB; Broad). (B) WT primary microglia were treated with either vehicle chloroquine (50 μM), MG132 (10 μM), or LPS (10 ng/mL) for the indicated amount of time (min). Western blot analysis was used to examine RIPK1 activation by immunoblotting for p-S166 RIPK1. Images are representative of two to three experiments. (C) WT primary microglia were treated with chloroquine (50 μM) in the presence of either vehicle or Nec-1s. Western blot analysis was used to examine RIPK1 activation by immunoblotting for p-S166 RIPK1. Images are representative of two experiments. (D) Microglia were isolated from adult WT, RIPK1ΔRIPK1, APP/PS1, and APP/PS1;RIPK1ΔRIPK1 mice (9 to 6 mo old) and analyzed by RNA-seq. Our coexpression analysis identified a module with ~149 genes that were up-regulated in APP/PS1 microglia and suppressed in APP/PS1;RIPK1ΔRIPK1 microglia (E). Pathways and processes that are enriched in the genes that are up-regulated in the APP/PS1-deriverted microglia vs. WT-derived microglia and the increase is attenuated in the APP/PS1;RIPK1ΔRIPK1 microglia. Analysis was done using gene set enrichment analysis (MSigDB; Broad). (F) The transcription factors that can regulate the expression of these 149 genes were also examined. Analysis was done using gene set enrichment analysis (MSigDB; Broad). Data are represented as an FDR q-value (x10^-5).

and identified that the top RIPK1-mediated pathways in microglia include the metabolism of biopolymers and nucleic acids (Fig. 5E). We also analyzed the genes differentially expressed in APP/PS1 microglia using MSigDB (Molecular Signatures Database) to identify transcription factors whose targets are overrepresented. Among these regulatory proteins, we identified a significant overrepresentation of predicted SP1 and cJUN transcription factor targets (Fig. 5F), which is consistent with previous reports of transcription factors associated with RIPK1 signaling (20, 21).

We next explored the possibility that some of the RIPK1-regulated genes identified here may be altered in other neurodegenerative and neuroinflammatory models. We found that the expression of at least eight RIPK1-regulated genes was also altered in the 5xFAD model of AD, in the SOD1G93A model of ALS, and in aging microglia (Fig. 6). One of the genes whose expression was altered in a RIPK1-dependent fashion was CH25h (Fig. 6A and B), a risk factor identified in LOAD (38). The expression of CH25h in BV2 cells was induced following IFNγ treatment in a
RIPK1-dependent manner (Fig. 6C). CH25H is a cell surface bound enzyme that is involved in cholesterol and lipid metabolism and mediates the production of 25-hydroxycholesterol. Previous studies have linked this gene to AD and an immunomodulatory pathway (7). Our data show that this enzyme is induced in primary microglia in a RIPK1-dependent manner in an AD mouse model.

Interestingly, a subset of the genes we identified as being up-regulated in microglia from APP/PS1 mice in a RIPK1-dependent manner were recently reported as top biomarkers associated with DAM in AD by a single-cell RNA-seq analysis (12) (see Fig. S5). We performed additional experiments to validate the expression of Cst7, a gene encoding a endosomal/lysosomal cathepsin known as cystatin F and normally expressed by immune cells (13), that was indeed regulated by RIPK1 in microglia; and, furthermore, its expression was also enhanced by IFNy in an RIPK1-dependent manner. (Fig. 6 D and E). Cst7 is massively induced in the CNS in microglia of SOD1 (G93A) transgenic mice (up to 52-fold) (39), aging microglia, during demyelination (40), and in a prion disease model (41). Our data show a robust increase of this transcript in APP/PS1 mice (Fig. 6D). To confirm that CST7 protein levels were also induced, we analyzed the expression of Cst7 in APP/PS1 by immunostaining using an anti-Cst7 antibody (42). The levels of Cst7 were increased in APP/PS1 mouse brains compared with WT animals (Fig. 7A). The aggregation of IBA1+ microglial cells around amyloid deposits is a hallmark of AD (43, 44). We found that Cst7 was highly expressed in the IBA1+ microglia around ThS+ plaques in the cortex of APP/PS1 mice (Fig. 7 B and C) while dispersed IBA1+ microglia were generally not positive for Cst7 (Fig. 7C).

Importantly, inhibition of RIPK1 in APP/PS1; RIPK1D138N microglia led to the loss of Cst7+/IBA1+ microglia. In human AD brains, we also detected increased levels of Cst7 RNA, as assessed by qPCR (Fig. 7D), and Cst7 protein, as assessed by immunostaining (Fig. 7E).

Our data suggest that CST7 levels are increased in microglia in APP/PS1 mice and in human AD brains. To examine whether increased Cst7 and Ch25h induction is localized in a subpopulation of microglial or macrophages, we performed FACS sorting experiments for CD11b+ cells that expressed different levels of CD45 (CD45low/intermediate vs. CD45high) (Fig. S6). Consistent with the notion that the CD11b+ CD45high cells represent macrophages and activated microglia (45), TREM2 surface levels were higher in this cell population compared with the CD11b+ CD45low/intermediate population (46) (Fig. S6 A and B). While RIPK1 and TREM1++ were expressed in both of these populations and their expressions were not altered in the APP/PS1 mice or by Nec-1s, there was a significant induction of both Cst7 and Ch25h in both CD45-expressing populations, which was attenuated by inhibition of RIPK1 (Fig. 7F). However, the fold induction of Cst7 in the APP/PS1 mice in the CD45high population is dramatically higher than that in the CD45low/intermediate population. These data confirm that Cst7 increase is predominantly in the activated or disease-associated microglia.

While previous reports have not fully elucidated the functional significance of DAM around amyloid plaques, the RIPK1-dependent induction of Cst7, a lysosomal cathepsin inhibitor, suggests that RIPK1 might regulate lysosomal function in microglia. To directly test this possibility, we transfected Cst7 into BV2 cells. We found that the expression of Cst7 led to the accumulation of p62 and LC3II, which was minimally further impacted upon the addition of lysosomal inhibitor chloroquine (Fig. 7G and Fig. S7). Thus, the increased expression of Cst7 can attenuate lysosomal function in a microglial cell line. Finally, we directly tested the effect of expressing Cst7 on intracellular cathepsin L activity and found that Cst7 overexpression attenuated activity in a dose-dependent manner in both BV2 cells and 293T cells (Fig. 7H). These data suggest that attenuation of lysosomal function, as it occurs in a subset of AD-associated microglia (47), may be in part regulated by RIPK1 signaling.

Discussion

In this study, we demonstrate that the levels of RIPK1 are elevated in microglia in postmortem cortical samples from AD patients and in a mouse model of AD. We show that inhibiting the kinase activity of RIPK1 is effective in inhibiting microglial inflammation in vitro and in an animal model of AD. We demonstrate that inhibition of RIPK1 leads to increased clearance of Aβ in vitro by microglia and reduction of amyloid plaques in the CNS, in vivo. In addition, the inhibition of RIPK1 was correlated with a significant improvement in memory defect of APP/PS1 mice. Two major hallmarks of AD pathogenesis are amyloid deposits comprised of Aβ fibrils and neuroinflammation. Microglia and macrophages are the major mediators of neuroinflammation in the CNS. Activation of these cells initiates the inflammatory cascade that results in the release of potentially neurotoxic cytokines to promote neurodegeneration. On the other hand, microglia are involved in uptake and removal of Aβ by phagocytosis and degradation in lysosomal cathepsins (48). However, persistent inflammation can impair the phagocytic ability of microglia through an unknown mechanism (49). Here, we show that promoting the expression of Cst7 in microglia by RIPK1 may be critical in reducing the phagocytic capacity of activated microglia. Since the generation and clearance of Aβ in the brain is subject to tight

**Fig. 6.** RIPK1-mediated transcriptional program impairs lysosomal function. (A) A multidisciplinary comparison of the transcription levels of several genes up-regulated in a RIPK1-dependent manner in APP/PS1 microglia vs. APP/PS1; RIPK1D138N microglia with the published datasets. Column 2, APP/PS1 vs. WT microglia; column 3, APP/PS1; RIPK1D138N vs. WT microglia; column 4, APP/PS1 vs. WT microglia (64); column 5, SxAD vs. WT microglia (65); column 6, LPS-stimulated vs. control microglia (66); column 7 microglia isolated from 4-mo-old mice vs. microglia isolated from 24-mo-old mice (67); column 8, microglia of SOD1G93A transgenic mice vs. WT control microglia (39). (B) A comparison of the transcript levels of CH25H in our microglia-derived RNA-seq dataset, whole brain tissue, and also a qPCR from a new cohort of brain-derived microglia in WT, RIPK1D138N, APP/PS1;WT, and APP/PS1;RIPK1D138N mice. (C) BV2 cells were treated with IFNγ in the presence or absence of Nec-1s. CH25H transcript levels were assessed by qPCR. (D) A comparison of the Cst7 transcript levels in our brain-derived microglia RNA-seq dataset, whole brain tissue, as well as qPCR from a new cohort of brain-derived microglia from WT, RIPK1D138N, APP/PS1;WT, and APP/PS1;RIPK1D138N mice. (E) BV2 cells were treated with IFNγ in the presence or absence of Nec-1s. Cst7 transcript levels were assessed by qPCR. *p < 0.05, **p < 0.01, ***p < 0.001. Student’s t test.
regulation, even a modest reduction in their clearance might be sufficient to lead to their accumulation and subsequent deposition into plaques to promote pathogenesis (50). Thus, effective modulation of neuroinflammation by inhibiting RIPK1 in the CNS might promote the clearance of Aβ species through microglia/macrophages by reducing the expression of Cst7. These data suggest that inhibition of RIPK1 is sufficient to reduce neuroinflammation mediated by microglia, which in turn reduces the formation of amyloid plaques and improves cognitive function, at least in the early stages of AD.

Fig. 7. CST7 is increased in AD. (A) Immunostaining using anti-CST7 antibody in slices from the WT and APP/PS1 mice in both the cortex and hippocampus (Hipp). (Bottom) Higher magnification of APP/PS1 slices in the cortex. Three WT and three APP/PS1 mice were used to validate this finding. (B) Immunostaining using anti-CST7 antibody in slices from APP/PS1 mice in the cortex followed by Ths+ staining. Two magnifications are shown. Three WT and three APP/PS1 mice were used to validate this finding. (C) Immunostaining using an anti-CST7 antibody and the microglial marker IBA1 in slices from WT, APP/PS1, and APP/PS1;RIPK1D138N. DAPI was used to stain nuclei. Three WT and three APP/PS1 animals were used to validate this finding. (D) RNA was isolated from postmortem tissue from control and AD patients. Levels of CST7 were examined by q-PCR. GAPDH was used as a housekeeping gene, and fold change was determined using the ΔΔCT method (**P < 0.01, Student’s t test; five control and five AD patients). (E) Immunostaining using anti-CST7 antibody in slices from the temporal lobe from control and AD patients. (Bottom) Higher magnification images from AD tissue. (F) Brain cells derived from WT or APP/PS1 animals (5 to 6 mo old) treated with either Nec-1s or vehicle for 1 mo were then FACS sorted based as CD11b+CD45low/intermediate vs. CD11b+CD45high cells. RNA levels of CST7 and Ch25H in both populations of cells (n = 3 to 4 animals per group, **P < 0.01, #P < 0.05 [APP/PS1 CD45 low/inter vs. APP/PS1 CD45 high], Student’s t test). (G) BV2 cells were transfected with either empty vector or a CST7 expressing plasmid overnight. The cells were then treated with either vehicle or chloroquine for 4 h. Western blot analysis was performed to examine RIPK1, p62, LC3, p-cJun and cJun levels. Beta actin was used as a loading control. Western blot images are representative of two experiments. (H) Vector or CST7 was transfected in HEK293T or BV2 cells, and cathepsin C activity was assessed by a fluorometric assay.

We show that reduction in protein turnover pathways mediated by proteasomes and lysosomes is sufficient to promote the activation of RIPK1. This is consistent with our previous observation where we show that optineurin deficiency promotes the activation of RIPK1 by reducing its turnover mediated by K48 ubiquitination (21). Defects in both the ubiquitin–proteasome (UPS) and lysosomal pathways have been found in AD (51, 52). We suggest that such defects in protein turnover in microglia might lead to the activation of RIPK1, which in turn promotes the transcription of genes such as Cst7 and a vicious cycle of microglial dysfunction.
and inflammation by further exacerbating phagocytic activity and lysosomal degradation.

Our results highlight the role of RIPK1 in mediating the microglial/macrophage disease-associated response in AD. These cells play an important role in mediating the disease progression of AD (53). Inhibition of RIPK1 by pharmacological or genetic means promoted the degradation of Aβ by microglia in vitro, as well as reduced amyloid plaque burden, and ameliorated the behavioral deficits observed in the APP/PS1 mice. Consistent with the role of RIPK1 in mediating neuroinflammatory response in the CNS, pharmacological inhibition of RIPK1 phenocopied the effect of genetic inactivation of RIPK1 in a variety of neuroinflammatory conditions, including TNFα-induced inflammation and animal models of AD, ALS, and multiple sclerosis (MS) (21, 22, 54). On the other hand, Nec-1s could not directly inhibit neuronal cell death induced by Aβ, suggesting that Nec-1s does not target Aβ or directly inhibit neuronal cell death. Inhibition of RIPK1 by Nec-1 has been shown to reduce the extent of injury in a variety of animal models (24), which is consistent with the role of RIPK1 as a key mediator of inflammation.

Our RNA-seq analysis of adult microglia identified CH25h, a susceptibility gene for late onset Alzheimer’s disease (38), as one of the RIPK1-regulated genes. The enzyme cholesterol 25-dihydroxylation (CH25h) catalyzes the rate-limiting step to synthesize the oxysterol 7α,25-dihydroxycholesterol (25HC) from cholesterol. 25HC is a potent corepressor of sterol regulatory element binding protein (SREBP) processing (55). Thus, CH25H is an important regulator of lipid metabolism. Interestingly, similar to that of Cst7, the transcriptional level of CH25H is also known to be upregulated in the spinal cord of patients with ALS (56). CH25H is also up-regulated in microglia after the induction of experimental autoimmune encephalomyelitis (EAE), an animal model for MS (57). CH25H deficiency significantly attenuated EAE disease course by limiting trafficking of pathogenic CD4+ T lymphocytes to the CNS. In macrophages, 25HC has been shown to be induced by infection and act as an amplifier of inflammatory signaling by regulating transcription (58). Chronic induction of CH25H has been proposed to contribute both to atherosclerosis and to AD (59). Thus, the role of RIPK1 in regulating the transcriptional induction of CH25H is also consistent with the recent report about the involvement of RIPK1 in atherosclerosis (60).

Cystatin F expression is found primarily in cells of the immune system, such as T cells, natural killer (NK) cells, and dendritic cells, and can bind and inhibit cathepsin C (13). In these peripheral immune populations, cystatin F activity inhibits endosomal/lysosomal cathepsins and contributes to cellular differentiation and functions (61, 62). Here, we show that the activation of RIPK1-mediated transcriptional response leads to a highly elevated production of Cst7, a cathepsin inhibitor, in activated microglia/macrophages around the amyloid plaques and in human AD pathological samples. Increased expression of Cst7 led to microglial dysfunction by blocking lysosomal trafficking. Importantly, inhibition of RIPK1 restored the normal levels of Cst7 expression in APP/PS1 mice. Since increased expression of Cst7 has been found in multiple animal models of neurodegenerative diseases, including in the microglia of SOD1(G93A) transgenic mice (39), in aging microglia, during demyelination (40), in a prion disease model (41), and in human AD, inhibition of RIPK1 may modulate a microglial inflammatory response common in multiple neurodegenerative diseases. Thus, inhibiting RIPK1 and thereby reducing Cst7 up-regulation may alleviate lysosomal distress in microglia, which is known to be present in AD and its animal models (63), and be beneficial for the treatment of various inflammatory disease indications. Furthermore, increased levels of Cst7 may provide an important biomarker for RIPK1-dependent inflammation in neurodegenerative diseases.

Materials and Methods

Animals. C57BL/6 (B6) mice were purchased from The Jackson Laboratory. All animals were maintained in a pathogen-free environment, and experiments on mice were conducted according to the protocols approved by the Harvard Medical School Animal Care Committee. B6C3-Tg(APPsw,PS1E9)5Bdwo/Mmjax (N9) C57BL/6 mice were purchased from JAX. Hemizygous B6C3-Tg(APPsw,PS1E9)5Bdwo/Mmjax (N9) C57BL/6 mice were used. RIPK1/Tg11 mice were a kind gift from Manolis Pasparakis, University of Cologne, Cologne, Germany.

Nec-1s Administration. The method of Nec-1s-R5-[(7-Chloro-1H-indol-3-yl)methyl]-3-methyl-2,4-imidazolidinedione formulation and delivery was previously described in ref. 14. Custom synthesized Nec-1s was first dissolved in DMSO (50% v/vol) and then transferred into 35% PEG solution, and this was suspended in water containing 2% sucrose. Mice were provided with vehicle control and Nec-1s as drinking water ad libitum. Each mouse drank vehicle or Nec-1s containing water about 5 to 10 mL/d (Nec-1s = 2.5 to 5 mg/dl).

Statistical Analysis. Data are expressed as mean ± SEM. Significance was assessed with Student’s t test or one-way ANOVA followed by Bonferroni’s post hoc test using Prism version 6.0 software (GraphPad).

ACKNOWLEDGMENTS. We thank Dr. Collin Watts (University of Dundee) for the anti-mouse Cst7 Ab. We thank Gary Kasof (Cell Signaling) for developing the phospho-S166 RIPK1 antibody. We thank Dr. Manolis Pasparakis (University of Cologne) for Ripk1Tg11 mice. We thank Dr. Barbara Caldarego (Neuro- Behavior Laboratory, Harvard Institute of Medicine) for conducting mouse behavior analysis. We thank Dr. Jennifer Walters and staff (Harvard Medical School Nikon microsscope facility) for help with fluorescence microscopy. We thank Dr. Matthew Frosh (Harvard Neuropathology Services) for providing human brain pathological samples. We acknowledge the support of an Aging and Disability Resource Center grant. This work was supported by National Institute of Neurological Disorders and Stroke Grant 1R01NS082257 and NIH Grant 1R01NS087231 (to Y.I.). D.O. was supported by a postdoctoral fellowship from the National Multiple Sclerosis Society and a National MS Society Career Transition Award. Y.I. was supported in part by postdoctoral fellowships from the Daichi Sankyo Foundation of Life Science, the Nakatomi Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Japan Society for the Promotion of Science. H.C. was supported by a scientific research training grant from Huazhong University of Science and Technology.


